NEKTAR THERAPEUTICS 2024-2025 Proxy Voting Records

Description as filed by funds: Election of Directors: Diana Brainard

NEKTAR THERAPEUTICS’s own tally for this item (“Elect Director: Diana Brainard”): 89,565,584 for, 12,398,258 against, per its Form 8-K filed May 28, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 Each of the individuals listed below was elected, by a majority of the votes cast at the Annual Meeting and entitled to vote on the election of directors, to serve on the board of directors of the Company (the "Board") until the Company's 2028 Annual Meeting of Stockholders.”
Support: 88% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 42 asset managers below reported 38,796,041 for, 2,708,919 against.

Showing the 25 largest of 42 asset managers. All 42 are in the interactive database (link above).

Description as filed by funds: Election of Directors: R. Scott Greer

NEKTAR THERAPEUTICS’s own tally for this item (“Elect Director: R. Scott Greer”): 87,246,490 for, 14,774,685 against, per its Form 8-K filed May 28, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1 Each of the individuals listed below was elected, by a majority of the votes cast at the Annual Meeting and entitled to vote on the election of directors, to serve on the board of directors of the Company (the "Board") until the Company's 2028 Annual Meeting of Stockholders.”
Support: 86% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 42 asset managers below reported 38,194,019 for, 3,310,941 against.

Showing the 25 largest of 42 asset managers. All 42 are in the interactive database (link above).

Description as filed by funds: To approve an amendment to our Certificate of Incorporation to effect, at the discretion of our board of directors on or prior to the one-year anniversary of the date of the Annual Meeting, a reverse stock split of our common stock at a stock split ratio between 1-for-2 and 1-for-40, with the final ratio to be determined by the board of directors in its sole discretion, the implementation and timing of which shall be subject to the sole discretion of the board of directors.

NEKTAR THERAPEUTICS’s own tally for this item (“6. The proposal to approve an amendment to our Certificate of Incorporation to effect, at the discretion of the Board on or prior to the one-year anniversary of the date of the Annual Meeting, a reverse stock split of ou”): 140,024,464 for, 9,746,710 against — passed, per its Form 8-K filed May 28, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 6 The proposal to approve an amendment to our Certificate of Incorporation to effect, at the discretion of the Board on or prior to the one-year anniversary of the date of the Annual Meeting, a reverse stock split of our common stock at a stock split ratio between 1-for-2 and 1-for-40, wit…”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 42 asset managers below reported 41,504,960 for.

Showing the 25 largest of 42 asset managers. All 42 are in the interactive database (link above).

Description as filed by funds: To approve an amendment to our Certificate of Incorporation to increase the number of authorized shares of our common stock from 300,000,000 shares to 390,000,000 shares.

NEKTAR THERAPEUTICS’s own tally for this item (“5. Proposal to approve an amendment to our Certificate of Incorporation to increase the number of authorized shares of our common stock from 300,000,000 shares to 390,000,000 shares”): 92,476,043 for, 55,481,313 against — passed, per its Form 8-K filed May 28, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 5 The proposal to approve an amendment to our Certificate of Incorporation to increase the number of authorized shares of our common stock from 300,000,000 shares to 390,000,000 shares was approved with the following votes.”
Support: 63% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 41 asset managers below reported 20,753,680 for, 20,643,864 against.

Showing the 25 largest of 41 asset managers. All 41 are in the interactive database (link above).

Description as filed by funds: To approve an amendment to our Amended and Restated 2017 Performance Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under the plan by 6,000,000 shares.

NEKTAR THERAPEUTICS’s own tally for this item (“2. Proposal to approve an amendment to the Amended and Restated 2017 Performance Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance thereunder by 6,000,000 shares”): 72,407,461 for, 28,767,636 against — passed, per its Form 8-K filed May 28, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2 The proposal to approve an amendment to the Amended and Restated 2017 Performance Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance thereunder by 6,000,000 shares was approved with the following votes.”
Support: 72% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 43 asset managers below reported 38,301,837 for, 3,208,034 against.

Showing the 25 largest of 43 asset managers. All 43 are in the interactive database (link above).

Description as filed by funds: To approve a non-binding advisory resolution regarding our executive compensation (a "say-on-pay" vote).

NEKTAR THERAPEUTICS’s own tally for this item (“4. Proposal to approve the non-binding advisory resolution regarding our executive compensation”): 96,965,611 for, 4,097,449 against — passed, per its Form 8-K filed May 28, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 4 The proposal to approve the non-binding advisory resolution regarding our executive compensation was approved with the following votes.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of NEKTAR THERAPEUTICS’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Advisory Vote to Ratify Named Executive Officers' Compensation” (2 managers, Fund and manager reports combined; may count the same shares twice; no share total shown); “Say on pay” (2 managers, 102 for).

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 41 managers: 41,346,732 for, 50,812 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports, all 109 managers: 58,531,160 for, 444,225 against, 10,000 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Description as filed by funds: To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.

NEKTAR THERAPEUTICS’s own tally for this item (“3. Proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025”): 147,989,026 for, 1,704,605 against — passed, per its Form 8-K filed May 28, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3 The proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 was approved with the following votes.”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 42 asset managers below reported 41,502,467 for, 2,493 against.

Showing the 25 largest of 42 asset managers. All 42 are in the interactive database (link above).